Colin Bristow

Stock Analyst at UBS

(0)
# 4908
Out of 5,329 analysts
96
Total ratings
21.62%
Success rate
-28.73%
Average return
23 Stocks
Name Action PT Current % Upside Ratings Updated
IMVT Immunovant
Downgrades: Neutral
38 17
15.96 6.52% 6 Apr 22, 2025
AMGN Amgen
Maintains: Neutral
315 319
283.67 12.45% 8 Apr 14, 2025
ABOS Acumen Pharmaceutica...
Maintains: Buy
6 4
1.07 273.83% 4 Mar 28, 2025
ENGN enGene Holdings
Downgrades: Neutral
34 7
3.65 91.78% 2 Feb 14, 2025
PFE Pfizer
Maintains: Neutral
29 28
23.91 17.11% 12 Feb 5, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
4 3
0.51 331.37% 5 Jan 27, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
125 120
83.31 44.04% 6 Jan 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
47 71
49.5 43.43% 3 Dec 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
70 96
103.22 -6.99% 3 Nov 21, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
562 586
498.44 17.57% 13 Nov 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
234 202
121 66.94% 10 Oct 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
56 16
1.76 809.09% 5 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
1090 1099
588.6 86.71% 1 Apr 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
56 54
7.88 585.28% 2 Mar 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
164 167
62.8 165.92% 5 Mar 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
428 420
794.79 -47.16% 1 Dec 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
12 2
7.01 -71.47% 2 Dec 8, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
18
0.86 1993.02% 1 Oct 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
154 146
193.41 -24.51% 2 Aug 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
73 75
49.49 51.55% 1 Jul 28, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
64 26
1.64 1485.37% 1 Apr 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
9
4.88 84.43% 1 Aug 23, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
195
n/a n/a 2 Feb 1, 2021